Palliative Surgery for Patients with Gastroesophageal Junction or Gastric Cancer: A Report on Clinical Observational Outcomes

被引:0
作者
Song, Yun [1 ]
Chen, Eunise [2 ]
Ikoma, Naruhiko [1 ]
Mansfield, Paul F. [1 ]
Bruera, Eduardo [3 ]
Badgwell, Brian D. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] UT Hlth, John P & Katherine G McGovern Med Sch, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, Houston, TX USA
关键词
Palliative surgery; Palliative care; Gastric cancer; Gastroesophageal junction cancer; Metastatic cancer; Malignant obstruction; Clinical observational outcomes; QUALITY-OF-LIFE; SURGICAL PALLIATION; SURVIVAL; INDICATORS; INPATIENTS; MORBIDITY;
D O I
10.1245/s10434-024-15416-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundFew studies have focused on palliative surgery in patients with advanced gastroesophageal junction (GEJ) or gastric cancer. We sought to evaluate clinical observational outcomes following palliative surgery in this population.Patients and MethodsPatients with GEJ or gastric cancer who underwent palliative surgery (1/2010-11/2022) were identified. The primary outcomes were symptom improvement, ability to tolerate an oral diet, discharge to home, 30 "good days" without hospitalization, and receipt of systemic treatment. Postoperative outcomes and survival were secondarily evaluated.ResultsAmong 93 patients, the median age was 59 (IQR 47-68) years, and the median Eastern Cooperative Oncology Group Performance Status (ECOG-PS) was 1 (range 0-3). The most frequent indication for palliative surgery was primary tumor obstruction [75 (81%) patients]. The most common procedures were feeding tube placement in 60 (65%) and intestinal bypass in 15 (16%) patients. A total of 75 (81%) patients experienced symptom improvement. Of these, 19 (25%) developed recurrent and 49 (65%) developed new symptoms. ECOG-PS was significantly associated with symptom-free time. Among those who underwent a bypass, resection, or ostomy creation for malignant obstruction, 16 (80%) tolerated an oral diet. Postoperatively, 87 (94%) were discharged home, 72 (77%) had 30 good days, and 64 (69%) received systemic treatment. Postoperative complications occurred in 35 (38%) patients, and 7 (8%) died within 30 days. The median survival time was 7.7 (95% CI 6.4-10.40) months.ConclusionsPatients with incurable GEJ or gastric cancer can benefit from palliative surgery. Prognosis and performance status should inform goals-of-care discussions and patient selection for surgical palliation.
引用
收藏
页码:5252 / 5262
页数:11
相关论文
共 50 条
  • [31] Association of Splenectomy With Postoperative Complications in Patients With Proximal Gastric and Gastroesophageal Junction Cancer
    Jürgen Weitz
    David P. Jaques
    Murray Brennan
    Martin Karpeh
    Annals of Surgical Oncology, 2004, 11 : 682 - 689
  • [32] Association of splenectomy with postoperative complications in patients with proximal gastric and gastroesophageal junction cancer
    Weitz, J
    Jaques, DP
    Brennan, M
    Karpeh, M
    ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (07) : 682 - 689
  • [33] Gastric cancer surgery in elderly patients
    Gretschel, Stephen
    Estevez-Schwarz, Lope
    Huenerbein, Michael
    Schneider, Ulrike
    Schlag, Peter M.
    WORLD JOURNAL OF SURGERY, 2006, 30 (08) : 1468 - 1474
  • [34] Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer
    Paschold, Lisa
    Binder, Mascha
    CURRENT ONCOLOGY, 2022, 29 (03) : 1430 - 1441
  • [35] Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer
    Chau, Ian
    Ayers, Dieter
    Goring, Sarah
    Cope, Shannon
    Korytowsky, Beata
    Abraham, Pranav
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (02) : 103 - 114
  • [36] Advances in the surgical management of gastric and gastroesophageal junction cancer
    Narayan, Raja R.
    Poultsides, George A.
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 6
  • [37] Outcomes of patients receiving urgent palliative radiotherapy for advanced lung cancer: an observational study
    Xu, Yang
    Trach, Celestee
    Tessier, Tracey
    Sinha, Rishi
    Skarsgard, David
    BMC PALLIATIVE CARE, 2024, 23 (01):
  • [38] Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High-Risk Gastric/Gastroesophageal Junction Cancer
    Liu, Qin
    Chu, Yanhong
    Shao, Jie
    Qian, Hanqing
    Yang, Ju
    Sha, Huizi
    Cen, Lanqi
    Tian, Manman
    Xu, Qiuping
    Chen, Fangjun
    Yang, Yang
    Wang, Weifeng
    Wang, Kai
    Yu, Lixia
    Wei, Jia
    Liu, Baorui
    ADVANCED SCIENCE, 2023, 10 (01)
  • [39] QOL assessment after palliative surgery for malignant bowel obstruction caused by peritoneal dissemination of gastric cancer: a prospective multicenter observational study
    Ito, Yuichi
    Fujitani, Kazumasa
    Sakamaki, Kentaro
    Ando, Masahiko
    Kawabata, Ryohei
    Tanizawa, Yutaka
    Yoshikawa, Takaki
    Yamada, Takanobu
    Hirao, Motohiro
    Yamada, Makoto
    Hihara, Jun
    Fukushima, Ryoji
    Choda, Yasuhiro
    Kodera, Yasuhiro
    Teshima, Shin
    Shinohara, Hisashi
    Kondo, Masato
    GASTRIC CANCER, 2021, 24 (05) : 1131 - 1139
  • [40] QOL assessment after palliative surgery for malignant bowel obstruction caused by peritoneal dissemination of gastric cancer: a prospective multicenter observational study
    Yuichi Ito
    Kazumasa Fujitani
    Kentaro Sakamaki
    Masahiko Ando
    Ryohei Kawabata
    Yutaka Tanizawa
    Takaki Yoshikawa
    Takanobu Yamada
    Motohiro Hirao
    Makoto Yamada
    Jun Hihara
    Ryoji Fukushima
    Yasuhiro Choda
    Yasuhiro Kodera
    Shin Teshima
    Hisashi Shinohara
    Masato Kondo
    Gastric Cancer, 2021, 24 : 1131 - 1139